U.S. Markets closed

AtriCure downgraded to Neutral from Overweight at Piper Jaffray

Piper Jaffray downgraded AtriCure citing uncertainty following the departure of the company's CFO and the suspension of its guidance. Piper cut its price target in half to $6 from $12. Note AtriCure shares were also downgraded this morning at JMP Securities.